Biogen Idec Issues Statement on U.S. Approval of AMPYRA™
News Jan 25, 2010
Biogen Idec has issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The U.S. FDA approval was granted on January 22, 2010.
AMPYRA will be marketed in the U.S by Acorda Therapeutics, Inc. AMPYRA is an extended release tablet formulation of the investigational drug dalfampridine. Biogen Idec will commercialize fampridine as a prolonged release tablet in markets outside of the U.S.
“For people with MS, impaired walking ability is one of the most common and concerning aspects of the disease,” said Alfred Sandrock, MD, PhD, senior vice president, Neurology Research and Development, Biogen Idec. “AMPYRA may be an important therapy in reducing the impact of this debilitating condition.”
“We congratulate our partner, Acorda Therapeutics, on this important achievement and look forward to working with regulators outside of the U.S. to make this therapy available to all people living with MS.”
On 12 January 2010, Biogen Idec announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for prolonged release fampridine tablets for the improvement of walking ability in adult patients with multiple sclerosis (MS). The company also has filed a New Drug Submission (NDS) to Health Canada.
New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-CigarettesNews
Data presented at the Society of Toxicology Annual Meeting (SOT) have demonstrated the potential of two different heat-not-burn tobacco products and e-cigarettes to reduce the risk of smoking-related diseases, in comparison to continued use of conventional cigarettes.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE